Chardan Capital Reaffirms “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Chardan Capital reissued their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report published on Thursday morning,Benzinga reports. Chardan Capital currently has a $7.00 target price on the stock.

Other analysts also recently issued reports about the stock. Canaccord Genuity Group dropped their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, JMP Securities reissued a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Taysha Gene Therapies presently has a consensus rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Down 9.3 %

TSHA stock opened at $2.06 on Thursday. The company’s 50 day moving average is $1.98 and its 200 day moving average is $2.38. The stock has a market cap of $422.18 million, a price-to-earnings ratio of 3.27 and a beta of 0.44. The company has a current ratio of 5.51, a quick ratio of 5.22 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 1-year low of $1.19 and a 1-year high of $4.32.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of large investors have recently bought and sold shares of TSHA. Creative Planning purchased a new stake in shares of Taysha Gene Therapies during the third quarter valued at approximately $28,000. Principal Financial Group Inc. bought a new stake in Taysha Gene Therapies during the 2nd quarter valued at $48,000. China Universal Asset Management Co. Ltd. raised its holdings in Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after buying an additional 17,446 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Taysha Gene Therapies during the 3rd quarter valued at $85,000. Finally, Scientech Research LLC bought a new stake in Taysha Gene Therapies in the 2nd quarter worth $97,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.